Published: 3 February 2024
Author(s): Muhammad Ahmad, Malik Waleed Zeb Khan, Shandana Ali, Salman Khan, Shakir Ullah
Issue: May 2024
Section: Letter to the Editor

We are writing to highlight the findings of a recent meta-analysis suggesting a possible relationship between the long-term use of angiotensin-converting enzyme inhibitors (ACEIs) and an increased risk of lung cancer [1]. ACEIs are commonly prescribed for hypertension, myocardial infarction, heart failure and renal disease due to improvements in both morbidity and mortality. ACEIs are generally considered safe and associated with significant patient adherence amongst antihypertensive medications, however, emerging evidence implies a nuanced interplay between these medications and lung cancer risk.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.